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Background: Deficiency of 3-hydroxy-isobutyryl-CoA hydrolase (HIBCH) caused by HIBCH mutations is a rare cerebral
organic aciduria caused by disturbance of valine catabolism. Multiple mitochondrial respiratory chain (RC) enzyme
deficiencies can arise from a number of mechanisms, including defective maintenance or expression of mitochondrial
DNA. Impaired biosynthesis of iron-sulphur clusters and lipoic acid can lead to pyruvate dehydrogenase complex
(PDHc) deficiency in addition to multiple RC deficiencies, known as the multiple mitochondrial dysfunctions syndrome.
Methods: Two brothers born to distantly related Pakistani parents presenting in early infancy with a progressive
neurodegenerative disorder, associated with basal ganglia changes on brain magnetic resonance imaging, were
investigated for suspected Leigh-like mitochondrial disease. The index case had deficiencies of multiple RC enzymes
and PDHc in skeletal muscle and fibroblasts respectively, but these were normal in his younger brother. The observation
of persistently elevated hydroxy-C4-carnitine levels in the younger brother led to suspicion of HIBCH deficiency, which
was investigated by biochemical assay in cultured skin fibroblasts and molecular genetic analysis.
Results: Specific spectrophotometric enzyme assay revealed HIBCH activity to be below detectable limits in cultured
skin fibroblasts from both brothers. Direct Sanger sequence analysis demonstrated a novel homozygous pathogenic
missense mutation c.950G>A; p.Gly317Glu in the HIBCH gene, which segregated with infantile-onset neurodegeneration
within the family.
Conclusions: HIBCH deficiency, a disorder of valine catabolism, is a novel cause of the multiple mitochondrial
dysfunctions syndrome, and should be considered in the differential diagnosis of patients presenting with multiple RC
deficiencies and/or pyruvate dehydrogenase deficiency.
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Mitochondrial disorders affect approximately 1 in 5000
births, and are clinically, biochemically and genetically
heterogeneous [1]. Combined deficiency of multiple
respiratory chain (RC) enzymes is one of the most frequent
findings in children with suspected mitochondrial disease,
representing approximately 30% of cases in whom a
biochemical abnormality is identified. Approximately
50% of patients with multiple RC deficiencies have
impaired replication or maintenance of the mitochon-
drial DNA (mtDNA), leading to progressive depletion
of mtDNA [2] or accumulation of multiple mtDNA
deletions. The remaining ~50% of cases have heteroge-
neous underlying causes, including mitochondrial or
nuclear-encoded defects of mitochondrial protein syn-
thesis [3] and the multiple mitochondrial dysfunctions
syndrome, in which the activity of PDHc is also impaired
[4-6]. Defects in mtDNA repair, maintenance or trans-
lation result in combined deficiency of complexes I, III
and IV (i.e. complexes that contain mtDNA-encoded
subunits) whereas the multiple mitochondrial dysfunc-
tions syndrome usually affects complexes containing
iron-sulphur (Fe-S) clusters (complexes I, II and III) as
well as PDHc.
Neurological features of cerebral organic acidurias
(disorders of degradation of the carbon skeleton of
amino acids) can be clinically and radiologically indis-
tinguishable from mitochondrial encephalomyopathies
caused by primary RC deficiencies; seizures, neurological
regression and bilateral symmetrical basal ganglia lesions
may occur in both groups of disorders [7-10]. 3-Hydroxy-
isobutyryl-CoA hydrolase (HIBCH) is a mitochondrial
enzyme that catalyses the fifth step of valine catabolism,
the conversion of 3-hydroxy-isobutyryl-CoA to 3-hydroxy-
isobutyrate (Figure 1a). HIBCH deficiency has previously
been reported in only two patients [11,12]. We now
describe two new genetically confirmed cases (siblings),
one of whom presented with combined defects of multiple
RC enzymes and the pyruvate dehydrogenase complex
(PDHc). This potentially represents a new disease mech-
anism mimicking the multiple mitochondrial dysfunctions
syndrome, namely degradation of multiple enzymes result-
ing from accumulation of a toxic metabolite methacrylyl-
CoA that is postulated to reduce mitochondrial enzyme
activities by reacting with exposed thiol groups.
Methods
Patient 1
The index case was the first child of healthy distantly
related Pakistani parents. He was born at term weighing
3.2 kg. There were no neonatal problems, but from
3 months he had developmental regression, with loss of
smile and progressive hypotonia. At 8 months Nissen
fundoplication was performed because of persistentvomiting. From 8 months he developed myoclonic jerks
and from 10 months recurrent generalised seizures.
Cerebrospinal fluid (CSF) lactate was mildly elevated at
2.2 mmol/l (reference range <2 mmol/l) at 8 months, with
a normal venous blood lactate of 1.7 mmol/l (reference
range < 1.8 mmol/l). A repeat CSF lactate was 3.5 mmol/l.
Histological examination of an open muscle biopsy per-
formed at 17 months revealed a mild increase in neutral
lipid droplets, but no ragged-red or cytochrome oxidase
(COX)-negative fibres. His clinical course was marked by
persistent vomiting and retching, despite the fundoplica-
tion, and extreme irritability and sleep disturbance. MRI
brain showed altered signal and atrophy in the globi pallidi
and relative sparing of the thalami. Leukoencephalopathy
and some generalised atrophy were also observed. He died
at 3 years of age.Patient 2
A younger sister of Patient 1 is currently well at 9 years
of age but the third child in the family, Patient 2, was a
boy born at term after a normal pregnancy, with a birth
weight of 2.9 kg. He presented on day 1 of life with
poor sucking and feeding difficulties. Feeding problems
continued and were associated with poor weight gain,
necessitating nasogastric tube feeding from 2 months.
Echocardiogram and ophthalmological examination were
normal at 4 months. He subsequently developed infantile
spasms, and hypsarrhythmia was observed on the electro-
encephalogram (EEG) at 7 months. The infantile spasms
responded dramatically to high dose prednisolone therapy.
He also had a progressive dystonic disorder and persistent
vomiting despite fundoplication (performed at 10 months),
associated with abdominal pain, extreme irritability, sleep
disturbance and breath-holding episodes leading to severe
oxygen desaturation. Venous blood lactate was elevated
at 4 mmol/l on one occasion but normal at other times
(Table 1). CSF lactate was mildly elevated on two occasions
at 2.1 and 2.6 mmol/l. The most significant biochemical ab-
normality was persistent elevation of hydroxy-C4-carnitine
(0.77 – 1.25 μmol/L, reference range <0.4; Figure 1b),
an investigation which was not available when Patient 1
was alive. Normal biochemical investigations included
very long chain fatty acids, transferrin electrophoresis,
purines, creatine kinase, cholesterol and triglycerides, CSF
neurotransmitters, urinary glycosaminoglycans and white
cell enzyme assays for lysosomal storage disorders.
Muscle biopsy showed mildly increased lipid deposition
within muscle fibres but no ragged-red or COX-negative
fibres. MRI brain at 11 months showed abnormal signal
within the dentate nuclei and the globi pallidi, with a
generalised lack of white matter (see Figure 2a and legend
for details of imaging appearances). Relentless progres-
sion led to death at 2 years 8 months.
Figure 1 HIBCH deficiency leads to accumulation of hydroxy-C4-carnitine. (a) Valine degradation pathway. 3-Hydroxy-isobutyrylCoA hydrolase
(HIBCH) catalyses the fifth step of valine catabolism. HIBCH deficiency leads to accumulation of 3-hydroxy-isobutyryl carnitine, which is detected as
hydroxy-C4-carnitine by tandem mass spectrometry. (b) Plasma acylcarnitine analysis by tandem mass spectrometry. Left panel: normal acylcarnitine
profile; Right panel: acylcarnitine profile from Patient 2 with accumulating hydroxy-C4-carnitine indicated by arrow.
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of Patients 1 and 2 (whose own parents were first cousins)
had a progressive neurological disorder from the age of
14 years, eventually leading to death at 46 years. His sister,
the maternal aunt of Patients 1 and 2, had a neuromuscu-
lar condition from birth, but normal cognition, and died
at 47 years.
Patient 3
Patient 3 is the first child of healthy unrelated white
European parents. He presented at 4 months with devel-opmental delay and ataxia and subsequent neurological
regression, and his case history has been reported previ-
ously [12]. We now present additional biochemical data
from this case, including muscle glutathione levels, and
compare his neuro-imaging features to those of Patient 2
(Figure 2b).
In all three cases, the following diagnostic investigations
were performed after informed parental consent. Clinical
and biochemical details of these 3 patients, and a fourth
patient previously reported in the literature (Brown et al.
[11]) are summarised in Table 1.
Table 1 Clinical and biochemical features of HIBCH deficiency
Patient 1 Patient 2 Patient 3 (previously reported
in Loupatty et al. 2007 [12])
Patient reported by
Brown et al. 1982 [11]
Gender Male Male Male Male
Age at presentation 3 months Birth 4 months Birth
Initial presentation Developmental regression Poor feeding Head bobbing Dysmorphic features
Age at death 3 years 2 years 8 months Alive at 8 years 3 months
Family history Distantly related British
Pakistani parents
Distantly related parents; younger
sibling of Patient 1
Unrelated parents First cousin Egyptian parents
Neonatal problems Vomiting Poor feeding Poor feeding Poor feeding
Hypotonia ++ ++ + ++
Dystonia + ++ ++ NS
Seizures Myoclonus from 8 months;
generalised seizures from 10 months
Infantile spasms From 9 months - transient absences
and episodes of eye rolling
NS
Developmental regression + + + NS
Episodes of acute encephalopathy No No + NS
Other clinical features Screaming episodes, sleep
disturbance, central apnoea, vision
impairment (optic atrophy), hearing
loss, microcephaly
Recurrent episodes of
screaming, breath-holding, poor
sleep, central apnoea, visual im-
pairment, microcephaly
Cerebellar ataxia - truncal ataxia,
dysmetria and intention tremor
Facial dysmorphism, tetralogy of Fallot,
multiple vertebral anomalies, agenesis
of cingulate gyrus and corpus callosum
(PM findings)
MRI brain Altered signal and atrophy in the
globi pallidi, with leukoencephalo-
pathy and some generalised atrophy
Abnormal signal within the dentate
nuclei and the globi pallidi, with a
generalised lack of white matter
(Figure 2a)
Signal abnormalities in globi
pallidi and midbrain and
asymmetric involvement of
cerebral peduncles (Figure 2b)
ND
Venous blood lactate (<2.0 mmol/L) 1.7 4.0, 1.6, 1.2 1.7 NS
CSF lactate (<2.0 mmol/L) 3.5, 2.2 2.1, 2.6 1.3 NS
Hydroxy-C4-carnitine (<0.4 µmol/L) ND 0.77-1.25 0.45-1.73 ND
Muscle respiratory chain enzyme activities (ratio to citrate synthase activity)
Complex I (0.104-0.268) 0.068 0.211 0.089 ND
Complexes II + III (0.040-0.204) 0.010 0.056 0.096 ND
Complex IV (COX) (0.014-0.034) 0.010 0.016 0.013 ND
Muscle glutathione levels
Muscle GSH (8.5-16.7 μmol/mg) ND ND 7.9 ND
Muscle mtDNA levels determined by Southern blot analysis
Muscle mtDNA (arbitrary units relative to the
multicopy nuclear 18S rRNA gene) Paediatric
controls (n = 7): Mean 17.3, SD 5.3, range
12.2 - 27.8
ND ND 29.5 ND
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Table 1 Clinical and biochemical features of HIBCH deficiency (Continued)
Fibroblast enzyme activities
PDHc (0.7-1.1 nmol/(min.mg)) 0.3 0.73 0.62 ND
COX (30–90 nmol/(min.mg)) 25 ND 117 ND
HIBCH (7.9 ± 1.3 nmol/(min.mg)) <2.6 <2.6 <2.6 ~20% of controls
HIBCH mutations Homozygous c.950G>A;
p.G317E
Homozygous c.950G>A; p.G317E Compound heterozygous
c.365A>G; p.Y122C and IVS2-3C>G;
p.R27fsX50
Homozygous c.219_220insTTGAATAG;
p.K73fsX86
Key: COX = cytochrome oxidase; GSH = glutathione; ND = not determined; NS = not stated in original report; PDHc = pyruvate dehydrogenase complex; PM = post mortem; numbers in bold are outside the reference
range, indicated in the left column.
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Figure 2 Magnetic resonance imaging of the brain in HIBCH deficiency. (a) Patient 2 at 9 months: axial T2 weighted image (left panel)
shows bilateral symmetrical signal hyperintensity within the globi pallidi (arrows) accompanied by signal hyperintensity on diffusion weighted
image (middle panel) and low signal on ADC map (right panel) in keeping with restricted diffusion which is beginning to pseudonormalise on
ADC map. The features are those of a subacute neurometabolic insult. In addition there is some generalised non-specific lack of cerebral volume
with prominence of the cerebral sulci and delay in myelin maturation. (b) Patient 3 at 11 months: axial T2 (far left) shows bilateral symmetrical
signal hyperintensity and swelling in the globi pallidi (arrows) with restricted diffusion (diffusion weighted image middle panel, ADC map right
panel) consistent with cytotoxic oedema. The imaging pattern is suggestive of an acute neurometabolic insult.
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Previously reported spectrophotometric assay methods
were used to determine the activities of RC enzyme
complexes I, II + III and IV in frozen skeletal muscle
homogenates [13] and complex IV in cultured skin fi-
broblasts [14]. Quantitative immunocytochemistry was
used to investigate relative expression of complex IV
subunit 1 (MTCO1) in patient and control fibroblasts,
which were cultured in the presence of 5 μM MitoTracker®
Red CM-H2-XRos (Molecular Probes Inc., Oregon) to
label mitochondria red, followed by green immunostaining
with an anti-MTCO1 monoclonal antibody (Clone 1D6E
1A8, Abcam) as described [15]. Densitometric analysis of
images captured using a Zeiss Axiophot epifluorescence
microscope was performed as reported previously [15]
and statistical analysis was performed using Student’s
t test. PDHc activity was measured in cultured skin
fibroblasts using a radiochemical method [16]. HIBCH
activity was determined by spectrophotometric enzymatic
assay using the physiological substrate S-3-hydroxyiso-
butyryl-CoA, as previously described [12]. Glutathione
in frozen skeletal muscle homogenates was assayed byelectrochemical high performance liquid chromatog-
raphy using a previously reported method [17].Molecular genetic analysis
Genomic DNA was extracted from cultured skin fibro-
blasts using standard methods. Exons and flanking in-
tronic sequences of the HIBCH gene were sequenced after
amplification by PCR from genomic DNA using intronic
primers with -21 M13 (5'-TGTAAAACGACGGCCAGT-3')
or M13-Rev (5'-CAGGAAACAGCTATGACC-3') extensions
(Additional file 1: Table S1). PCR fragments were sequenced
with -21 M13 and M13-Rev sequence primers using BigDye
Terminator cycle sequencing kits (Applied Biosystems,
Foster City, CA, USA). Sequence data were compared to
the reference HIBCH sequence (GenBank accession num-
ber, NM_014362.2) with nucleotide numbering starting at
the first adenine of the translation initiation codon ATG.
All diagnostic investigations were performed after
obtaining informed parental consent. This study was
approved by the National Research Ethics Committee
London Bloomsbury, UK.
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Biochemical analyses
Patient 1 had combined mitochondrial enzyme defects
involving PDHc and multiple RC enzymes: residual enzyme
activities in skeletal muscle were 65%, 25% and 71% of the
lowest control for complexes I, II + III and IV respectively,
whilst fibroblast PDHc activity was 43% of the lowest
control (Table 1). RC and PDHc activities were normal
in Patient 2, whilst Patient 3 had mild reduction of com-
plexes I and IV in skeletal muscle (Table 1). Quantitative
immunocytochemistry confirmed significantly decreased
expression of complex IV subunit I in cultured skin fibro-
blasts from Patient 3 (Figure 3); mean cellular MTCOI
expression in Patient 3 fibroblasts was 66% compared
to controls (p < 0.001). The presence of persistently elevated
plasma hydroxy-C4-carnitine in Patients 2 and 3 suggested
the possibility of HIBCH deficiency, which was confirmed
by enzyme assay; fibroblast HIBCH activity was below
detectable limits in all three patients (Table 1).
Molecular genetic analysis
Sequence analysis revealed a novel homozygous missense
mutation c.950G>A;p.Gly317Glu in the HIBCH gene on
chromosome 2q32.3 in both Patients 1 and 2 (Figure 4).
The mutation is absent in the dbSNP and 1000 genomes
databases (which includes 200 Pakistani alleles), affects an
amino acid residue highly conserved among different spe-
cies and is predicted by the SIFT software as deleterious
and by the Polyphen-2 software as probably damaging.
Parents and the maternal aunt and uncle were all het-
erozygous for the c.950G>A mutation. Patients 1 and 2
were also homozygous for two known single nucleotide
polymorphisms within the HIBCH gene: c.2T>C;p.Met1?
(disruption main translation initiation codon; initiation 5Figure 3 Cytochrome oxidase immunocytochemistry in cultured skin
and Patient 3 fibroblasts. Cells were cultured in the presence of 5 μM Mito
immunostaining with anti-MTCO1 antibodies and blue nuclear counterstainin
cellular expression levels of MTCO1 in Control (blue bars) and Patient (red bar
images of 3631 control and 2184 patient cells, and the ratio of the two signal
with a particular MTCO1/MitoTracker ratio at intervals of 0.025. The total numbcodons downstream). and c.136A>G;p.Thr46Ala. The
reported Minor Allele Frequencies for the two polymor-
phisms are for c.2T>C: T = 0.3988 (European American)
and C = 0.4557 (African American); and for c.136A>G:
A = 0.2407 (European American) and A = 0.3443 (African
American).
Molecular analysis of Patient 3 has previously been
reported [12].
Discussion
Two brothers with a progressive neurodegenerative
disorder are reported. Patient 1 had combined mitochon-
drial enzyme defects involving PDHc and multiple RC
enzymes (complexes I, II + III and IV, Table 1) whereas
these were normal in Patient 2. However, the remarkably
similar clinical features in both brothers implied that
they had the same underlying condition. The presence
of persistently elevated plasma hydroxy-C4-carnitine in
Patient 2 (Figure 1b, Table 1) suggested the possibility
of HIBCH deficiency, which was confirmed by enzyme
assay in cultured skin fibroblasts and molecular genetic
analysis. Fibroblast HIBCH activity was below detectable
limits in both patients (Table 1), and sequence analysis
revealed a homozygous missense mutation c.950G>A
(p.Gly317Glu) in the HIBCH gene (Figure 4). The causal
nature of this mutation is indicated by the fact that this
mutation 1) concerns a highly conserved amino acid; 2)
is predicted in silico to be deleterious and probably
damaging; 3) is the only putative mutation in the coding
region of the HIBCH gene encoding HIBCH, an enzyme
which was fully deficient in the patients; and 4) has not
been observed previously in genome databases, including
200 ethnically matched control alleles. Finally, thefibroblasts. Expression of complex IV subunit 1 (MTCO1) in control
Tracker® Red CM-H2-XRos to label mitochondria red, followed by green
g with DAPI. (a) Pseudo-coloured fluorescent micrographs. (b) Relative
s) cells. The mean grey levels were measured for both the green and red
s was calculated for each cell. The histogram reveals the frequency of cells
er of cells per culture is 100%.
Figure 4 Homozygous HIBCH mutation in patients 1 and 2. Sequence electropherograms of HIBCH gene. Top panel: Control; Second (from
top) panel: Patient 1; Third panel: Patient 2; Fourth panel: Mother; Fifth panel: Father. Both patients are homozygous for the c.950G>A mutation,
whilst the parents are heterozygous.
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family and was heterozygous in the unaffected parents
and the maternal aunt and uncle who had a different
neurological phenotype. Although we performed extensive
metabolic investigations in Patient 1 which did not reveal
any other metabolic disturbances, we cannot completely
exclude the small possibility that a second autosomal
recessive disorder may have been present, which could
have accounted for the more severe biochemical defects
observed in this patient.
HIBCH deficiency has been reported in only two cases
previously including Patient 3 [11,12]. Table 1 summa-
rises the clinical and biochemical findings in all 4
cases. Consistent features of this condition appear to
be hypotonia, poor feeding and developmental regression
with seizures starting in infancy (Table 1) and symmetrical
involvement of the globi pallidi seen on brain MRI. Images
were no longer available from Patient 1 for review, but
acute changes suggestive of cytotoxic oedema, shown
by imaging changes of restricted diffusion with subsequent
evolution to mature scarring, were seen in Patient 2
and also in Patient 3 (previously reported in [12]). Thesubthalamic regions were also involved in Patient 3. The
predilection for the basal ganglia in HIBCH deficiency is
intriguing, and the pathomechanism(s) underlying the
basal ganglia lesions, and in particular the selective
involvement of the globi pallidi and subthalamic nuclei,
are not clear. It is possible that the lesions arise from
localised cerebral energy failure and subsequent neuronal
cell death, as in other mitochondrial diseases including
Leigh syndrome (subacute necrotizing encephalomy-
elopathy) and Kearns-Sayre syndrome [7,8]. Alternatively,
the underlying pathological mechanisms and the imaging
changes may more closely resemble those seen in other
organic acidurias, such as glutaric aciduria type I and
methylmalonic and propionic acidurias, which remain
poorly understood [9,10]. However one hypothesis suggests
that one mechanism involves reaction of acrylyl-CoA
and glutaconyl-CoA with thiol groups [18] and gluta-
thione depletion has been noted in methylmalonic acid-
aemia (MMA) [19]. It is also interesting to note that
there is some evidence for secondary RC defects as a
possible mechanism of basal ganglia damage in these
organic acidaemias [20,21], and one study demonstrated
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well as inhibition of complex III and the α-ketoglutarate
dehydrogenase complex [22].
Most cases of multiple RC deficiencies reported in
the literature are caused by defects of maintenance or
translation of the mtDNA. The former group includes
defects of nuclear genes involved in replication of the
mtDNA and defects of nucleoside salvage necessary to
provide dNTP building blocks for mtDNA synthesis
[23]. In the previously reported Patient 3, mtDNA copy
number was normal in skeletal muscle (Table 1) and
cultured myoblasts and skin fibroblasts (data not shown),
excluding the possibility of mtDNA depletion as the cause
of the mild RC defects observed in this patient. Disorders
of mitochondrial translation may be primary mtDNA
defects, such as deletions of mtDNA or point mutations
involving the mitochondrial transfer RNA genes, or
nuclear gene defects [3]. In a small number of cases,
a combined deficiency of multiple RC enzymes associated
with PDHc deficiency has been reported, the so-called
multiple mitochondrial dysfunctions syndrome. Recently,
mutations in two Fe-S cluster assembly proteins were
shown to cause multiple mitochondrial enzyme defects
including PDHc deficiency. Mutations in NFU1, required
late in the maturation of Fe-S clusters, caused a syndrome
of fatal infantile encephalopathy and/or pulmonary hyper-
tension in Spanish and Mexican families with combined
defects of PDHc, complex II, lipoic acid synthase and
the glycine cleavage system [5,6]. Patients with mutations
in BOLA3, which is also needed for Fe-S and lipoic acid
biosynthesis, have a similar biochemical phenotype [6,24],
but the precise pattern of RC deficiencies in these defects
differs according to the specific Fe-S cluster synthesis
pathway that is impaired [6].
With respect to the pathological mechanism under-
lying HIBCH deficiency, methacrylyl-CoA, a proximal
metabolite in the valine degradation pathway (Figure 1a),
could well play a causative role. Cysteine and cysteamine
conjugates of methacrylyl-CoA were shown to accumulate
in multiple tissues, particularly liver, kidney and brain, in
the first patient reported with HIBCH deficiency [11].
Cysteine is a non-essential amino acid bearing a thiol side
chain that is frequently involved in enzymatic reactions
and is susceptible to oxidation, leading to formation of the
disulphide cystine. Cystine plays an important structural
role in many proteins; disulphide bonds are important
in crosslinking proteins, serving to increase rigidity and
conferring resistance to proteolytic degradation. Methacry-
lyl-CoA could react with mitochondrial enzymes containing
essential cysteine residues, including PDHc and RC
enzymes [25-29], thereby reducing their activities. De-
pletion of cysteine also could lead to reduced activity of
mitochondrial enzymes containing Fe-S clusters (e.g.
RC complexes I, II and III and the Krebs cycle enzymeaconitase), since cysteine provides sulphide for Fe-S
clusters. The ability of thiol groups to undergo redox
reactions confers antioxidant properties to cysteine, most
importantly in the tripeptide glutathione (composed of
cysteine, glycine and glutamic acid) and also in mitochon-
drial thioredoxin. Thioredoxin contains two cysteine
residues in its active centre that undergo reversible
oxidation/reduction in response to mitochondrial redox
status [30]. Depletion of mitochondrial pools of cysteine,
glutathione and thioredoxin by methacrylyl-CoA could
lead to oxidative damage, with further impairment of RC
enzyme function. Indeed, we found mildly reduced muscle
glutathione in Patient 3, who also had mildly reduced
activities of RC complexes I and IV in muscle (Table 1),
and significantly decreased expression of complex IV
subunit I in fibroblasts measured by quantitative im-
munocytochemistry (Figure 3). These effects are likely
to vary according to the levels of oxidative stress, which
may explain the variable RC and PDHc defects seen in
the 3 patients with HIBCH deficiency (Table 1). We have
previously demonstrated reversibility of RC defects in
Patient 3, who had normal activities of complexes I-IV in
a biopsy performed 3 months after the abnormal biopsy
shown in Table 1 with mildly reduced complex I and
IV levels (Loupatty et al. 2007 [12]). A reduced plasma
concentration of glutathione has been found in both
mitochondrial disorders and organic acidaemias [31,32].
Complex I dysfunction was linked to Parkinson’s disease
(PD) following the observation of a high incidence of PD
in subjects who had recreationally misused 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a known
inhibitor of complex I [33] and glutathione depletion has
been noted to precede complex I deficiency in PD [34].
Increased oxidation of six complex I cysteine residues
was demonstrated in glutathione-depleted mouse brains,
an oxidative stress model of murine PD [35]. Methacrylyl-
CoA acid could further disrupt enzymatic reactions taking
place in mitochondria by irreversibly binding cofactors
such as CoA and lipoic acid. Lack of CoA would be
expected to inhibit the Krebs cycle, whilst lipoate is an
essential component of PDHc.
Toxic damage to mitochondrial enzymes has previously
been demonstrated in ethylmalonic encephalopathy. In
affected patients mutations of the ETHE1 sulphur diox-
ygenase lead to accumulation of sulphide, which affects
the function of complex IV and the short chain acyl-CoA
dehydrogenase involved in mitochondrial fatty acid oxida-
tion [36,37]. By contrast, complex IV activity appears to
be only mildly reduced in HIBCH deficiency, with rela-
tively greater effects on complex I and PDHc observed in
Patient 1 in this study.
These cases illustrate the clinical utility of acylcarnitine
analysis in the differential diagnosis of suspected mito-
chondrial disease. The older brother Patient 1 had died
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into routine metabolic clinical practice, but the persistently
elevated hydroxy-C4-carnitine levels in his younger brother
Patient 2 eventually led to the correct diagnosis of HIBCH
deficiency. Acylcarnitine analysis is a useful investigation
in other cases of suspected mitochondrial disease, since
it may help to direct diagnostic genetic investigations,
for example succinyl and propionyl carnitines may be
elevated in patients with succinyl-CoA ligase deficiency
caused by SUCLA2 or SUCLG1 mutations [38,39].
Conclusions
In conclusion, HIBCH deficiency should be considered
in the differential diagnosis for patients with multiple RC
defects, including those with associated PDHc deficiency.
Moreover, the presence of hydroxy-C4-carnitine in the
acylcarnitine profile should alert the clinician to the possi-
bility of this condition. Our results stress the importance
of acylcarnitine analysis in patients with suspected mito-
chondrial disease.
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sequence analysis of HIBCH.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SF performed biochemical studies, interpreted data and revised manuscript.
HRW performed molecular genetic studies, interpreted data and revised
manuscript. SJRH, GB, IPH, J-WT, RG, LA, RJAW acquired and interpreted data.
PTC and JVL interpreted data and revised manuscript. SR conceived study,
acquired and interpreted data, and wrote manuscript. All authors read and
approved the final manuscript.
Acknowledgements
SR and PTC are supported by Great Ormond Street Hospital Children’s Charity.
Author details
1Academic Medical Centre, Laboratory Genetic Metabolic Diseases, University
of Amsterdam, Amsterdam, The Netherlands. 2Chemical Pathology, Great
Ormond Street Hospital, London, UK. 3Diagnostic Imaging, Great Ormond
Street Hospital, London, UK. 4Metabolic Unit, Great Ormond Street Hospital,
London, UK. 5Neurometabolic Unit, National Hospital for Neurology, London,
UK. 6Mitochondrial Research Group, Clinical and Molecular Genetics Unit,
UCL Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK.
7Department of Biochemistry, University of Oxford, Oxford, UK. 8Department
of Clinical Neurosciences, UCL Institute of Neurology, London, UK.
Received: 22 June 2013 Accepted: 9 November 2013
Published: 4 December 2013
References
1. Rahman S, Hanna MG: Diagnosis and therapy in neuromuscular disorders:
diagnosis and new treatments in mitochondrial diseases. J Neurol
Neurosurg Psychiatry 2009, 80:943–953.
2. Sarzi E, Bourdon A, Chretien D, Zarhrate M, Corcos J, Slama A, de Lonlay P,
Cormier-Daire V, Rotig A, Munnich A: Mitochondrial DNA depletion is a
prevalent cause of multiple respiratory chain deficiency in childhood.
J Pediatr 2007, 150:531–534.3. Chrzanowska-Lightowlers ZM, Horvath R, Lightowlers RN: 175th ENMC
International Workshop: mitochondrial protein synthesis in health and
disease, 25-27th June 2010, Naarden, The Netherlands. Neuromuscul Disord
2011, 21:142–147.
4. Rouault TA: Biogenesis of iron-sulfur clusters in mammalian cells: new
insights and relevance to human disease. Dis Model Mech 2012, 5:155–164.
5. Navarro-Sastre A, Tort F, Stehling O, Uzarska MA, Arranz JA, Del TM, Labayru MT,
Landa J, Font A, Garcia-Villoria J, et al: A fatal mitochondrial disease is
associated with defective NFU1 function in the maturation of a subset
of mitochondrial Fe-S proteins. Am J Hum Genet 2011, 89:656–667.
6. Cameron JM, Janer A, Levandovskiy V, Mackay N, Rouault TA, Tong WH,
Ogilvie I, Shoubridge EA, Robinson BH: Mutations in iron-sulfur cluster
scaffold genes NFU1 and BOLA3 cause a fatal deficiency of multiple
respiratory chain and 2-oxoacid dehydrogenase enzymes. Am J Hum
Genet 2011, 89:486–495.
7. Rahman S, Blok RB, Dahl HH, Danks DM, Kirby DM, Chow CW, Christodoulou J,
Thorburn DR: Leigh syndrome: clinical features and biochemical and DNA
abnormalities. Ann Neurol 1996, 39:343–351.
8. Valanne L, Ketonen L, Majander A, Suomalainen A, Pihko H:
Neuroradiologic findings in children with mitochondrial disorders.
AJNR Am J Neuroradiol 1998, 19:369–377.
9. Harting I, Neumaier-Probst E, Seitz A, Maier EM, Assmann B, Baric I, Troncoso M,
Muhlhausen C, Zschocke J, Boy NP, et al: Dynamic changes of striatal and
extrastriatal abnormalities in glutaric aciduria type I. Brain 2009,
132:1764–1782.
10. Harting I, Seitz A, Geb S, Zwickler T, Porto L, Lindner M, Kolker S, Horster F:
Looking beyond the basal ganglia: the spectrum of MRI changes in
methylmalonic acidaemia. J Inherit Metab Dis 2008, 31:368–378.
11. Brown GK, Hunt SM, Scholem R, Fowler K, Grimes A, Mercer JF, Truscott RM,
Cotton RG, Rogers JG, Danks DM: Beta-hydroxyisobutyryl coenzyme a
deacylase deficiency: a defect in valine metabolism associated with
physical malformations. Pediatrics 1982, 70:532–538.
12. Loupatty FJ, Clayton PT, Ruiter JP, Ofman R, Ijlst L, Brown GK, Thorburn DR,
Harris RA, Duran M, Desousa C, et al: Mutations in the gene encoding 3-
hydroxyisobutyryl-CoA hydrolase results in progressive infantile
neurodegeneration. Am J Hum Genet 2007, 80:195–199.
13. Hargreaves P, Rahman S, Guthrie P, Taanman JW, Leonard JV, Land JM,
Heales SJ: Diagnostic value of succinate ubiquinone reductase activity in
the identification of patients with mitochondrial DNA depletion. J Inherit
Metab Dis 2002, 25:7–16.
14. Hayasaka K, Brown GK, Danks DM, Droste M, Kadenbach B: Cytochrome c
oxidase deficiency in subacute necrotizing encephalopathy (Leigh
syndrome). J Inherit Metab Dis 1989, 12:247–256.
15. Taanman JW, Muddle JR, Muntau AC: Mitochondrial DNA depletion can
be prevented by dGMP and dAMP supplementation in a resting culture
of deoxyguanosine kinase-deficient fibroblasts. Hum Mol Genet 2003,
12:1839–1845.
16. Wicking CA, Scholem RD, Hunt SM, Brown GK: Immunochemical analysis
of normal and mutant forms of human pyruvate dehydrogenase.
Biochem J 1986, 239:89–96.
17. Hargreaves IP, Sheena Y, Land JM, Heales SJ: Glutathione deficiency in
patients with mitochondrial disease: implications for pathogenesis and
treatment. J Inherit Metab Dis 2005, 28:81–88.
18. Lehnert W, Sass JO: Glutaconyl-CoA is the main toxic agent in glutaryl-CoA
dehydrogenase deficiency (glutaric aciduria type I). Med Hypotheses 2005,
65:330–333.
19. Treacy E, Arbour L, Chessex P, Graham G, Kasprzak L, Casey K, Bell L, Mamer O,
Scriver CR: Glutathione deficiency as a complication of methylmalonic
acidemia: response to high doses of ascorbate. J Pediatr 1996, 129:445–448.
20. Okun JG, Horster F, Farkas LM, Feyh P, Hinz A, Sauer S, Hoffmann GF,
Unsicker K, Mayatepek E, Kolker S: Neurodegeneration in methylmalonic
aciduria involves inhibition of complex II and the tricarboxylic acid cycle,
and synergistically acting excitotoxicity. J Biol Chem 2002, 277:14674–14680.
21. de Keyzer Y, Valayannopoulos V, Benoist JF, Batteux F, Lacaille F, Hubert L,
Chretien D, Chadefeaux-Vekemans B, Niaudet P, Touati G, et al: Multiple OXPHOS
deficiency in the liver, kidney, heart, and skeletal muscle of patients with
methylmalonic aciduria and propionic aciduria. Pediatr Res 2009, 66:91–95.
22. Schwab MA, Sauer SW, Okun JG, Nijtmans LG, Rodenburg RJ, van den
Heuvel LP, Drose S, Brandt U, Hoffmann GF, Ter LH, et al: Secondary
mitochondrial dysfunction in propionic aciduria: a pathogenic role for
endogenous mitochondrial toxins. Biochem J 2006, 398:107–112.
Ferdinandusse et al. Orphanet Journal of Rare Diseases 2013, 8:188 Page 11 of 11
http://www.ojrd.com/content/8/1/18823. Rahman S, Poulton J: Diagnosis of mitochondrial DNA depletion
syndromes. Arch Dis Child 2009, 94:3–5.
24. Haack TB, Rolinski B, Haberberger B, Zimmermann F, Schum J, Strecker V,
Graf E, Athing U, Hoppen T, Wittig I, et al: Homozygous missense mutation
in BOLA3 causes multiple mitochondrial dysfunctions syndrome in two
siblings. J Inherit Metab Dis 2012.
25. Schwartz ER, Reed LJ: Alpha-keto acid dehydrogenase complexes. 13.
Reaction of sulfhydryl groups in pyruvate dehydrogenase with organic
mercurials. J Biol Chem 1970, 245:183–187.
26. Khailova LS, Korochkina LG, Severin SE: Organization and functioning of
muscle pyruvate dehydrogenase active centers. Ann N Y Acad Sci 1989,
573:36–54.
27. Ali MS, Roche TE, Patel MS: Identification of the essential cysteine residue
in the active site of bovine pyruvate dehydrogenase. J Biol Chem 1993,
268:22353–22356.
28. Burwell LS, Nadtochiy SM, Tompkins AJ, Young S, Brookes PS: Direct evidence
for S-nitrosation of mitochondrial complex I. Biochem J 2006, 394:627–634.
29. Cooperstein SJ: Reversible inactivation of cytochrome oxidase by
disulfide bond reagents. J Biol Chem 1963, 238:3606–3610.
30. Chen Y, Yu M, Jones DP, Greenamyre JT, Cai J: Protection against oxidant-
induced apoptosis by mitochondrial thioredoxin in SH-SY5Y neuroblast-
oma cells. Toxicol Appl Pharmacol 2006, 216:256–262.
31. Salmi H, Leonard JV, Rahman S, Lapatto R: Plasma thiol status is altered
in childrenwithmitochondrial diseases. Scand J Clin Lab Invest 2012, 72:152–157.
32. Salmi H, Leonard JV, Lapatto R: Patients with organic acidaemias have an
altered thiol status. Acta Paediatr 2012, 101:e505–e508.
33. Langston JW, Ballard P, Tetrud JW, Irwin I: Chronic Parkinsonism in humans
due to a product of meperidine-analog synthesis. Science 1983, 219:979–980.
34. Perry TL, Godin DV, Hansen S: Parkinson's disease: a disorder due to nigral
glutathione deficiency? Neurosci Lett 1982, 33:305–310.
35. Danielson SR, Held JM, Oo M, Riley R, Gibson BW, Andersen JK: Quantitative
mapping of reversible mitochondrial complex I cysteine oxidation in a
parkinson disease mouse model. J Biol Chem 2011, 286:7601–7608.
36. Tiranti V, D'Adamo P, Briem E, Ferrari G, Mineri R, Lamantea E, Mandel H,
Balestri P, Garcia-Silva MT, Vollmer B, et al: Ethylmalonic encephalopathy is
caused by mutations in ETHE1, a gene encoding a mitochondrial matrix
protein. Am J Hum Genet 2004, 74:239–252.
37. Tiranti V, Viscomi C, Hildebrandt T, Di MI, Mineri R, Tiveron C, Levitt MD,
Prelle A, Fagiolari G, Rimoldi M, et al: Loss of ETHE1, a mitochondrial
dioxygenase, causes fatal sulfide toxicity in ethylmalonic
encephalopathy. Nat Med 2009, 15:200–205.
38. Elpeleg O, Miller C, Hershkovitz E, Bitner-Glindzicz M, Bondi-Rubinstein G,
Rahman S, Pagnamenta A, Eshhar S, Saada A: Deficiency of the ADP-forming
succinyl-CoA synthase activity is associated with encephalomyopathy and
mitochondrial DNA depletion. Am J Hum Genet 2005, 76:1081–1086.
39. Van Hove JL, Saenz MS, Thomas JA, Gallagher RC, Lovell MA, Fenton LZ,
Shanske S, Myers SM, Wanders RJ, Ruiter J, et al: Succinyl-CoA ligase
deficiency: a mitochondrial hepatoencephalomyopathy. Pediatr Res 2010,
68:159–164.
doi:10.1186/1750-1172-8-188
Cite this article as: Ferdinandusse et al.: HIBCH mutations can cause
Leigh-like disease with combined deficiency of multiple mitochondrial
respiratory chain enzymes and pyruvate dehydrogenase. Orphanet
Journal of Rare Diseases 2013 8:188.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
